Furthermore, it has been proposed that the therapeutic index for NAMPT inhibitors can be increased in patients whose cancers lack NAPRT1, an essential enzyme in an alternative NAD synthesis pathway that utilizes nicotinic acid (NA, naicin, vitamin B3) as a starting point [15]. Here, NAPRT is linked to cancer.